AU779772B2 - Diagnostic and therapeutics for sepsis - Google Patents

Info

Publication number

AU779772B2

AU779772B2 AU39956/00A AU3995600A AU779772B2 AU 779772 B2 AU779772 B2 AU 779772B2 AU 39956/00 A AU39956/00 A AU 39956/00A AU 3995600 A AU3995600 A AU 3995600A AU 779772 B2 AU779772 B2 AU 779772B2

Authority

AU

Australia

Prior art keywords

allele

sepsis

pattern

subject

primer

Prior art date

1998-10-30

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Links

• Espacenet
• Global Dossier
• Discuss

• 206010040047 Sepsis Diseases 0.000 title claims abstract description 139
• 239000003814 drug Substances 0.000 title description 16
• 238000000034 method Methods 0.000 claims abstract description 100
• 108700028369 Alleles Proteins 0.000 claims description 205
• 108010002352 Interleukin-1 Proteins 0.000 claims description 154
• 102000000589 Interleukin-1 Human genes 0.000 claims description 145
• 150000007523 nucleic acids Chemical class 0.000 claims description 53
• 102000039446 nucleic acids Human genes 0.000 claims description 48
• 108020004707 nucleic acids Proteins 0.000 claims description 48
• 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 claims description 40
• 108091034117 Oligonucleotide Proteins 0.000 claims description 40
• 239000003550 marker Substances 0.000 claims description 39
• 230000000694 effects Effects 0.000 claims description 37
• 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 claims description 34
• 238000001514 detection method Methods 0.000 claims description 34
• 238000003556 assay Methods 0.000 claims description 29
• 238000009396 hybridization Methods 0.000 claims description 28
• 238000004458 analytical method Methods 0.000 claims description 27
• 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 claims description 26
• 230000003321 amplification Effects 0.000 claims description 26
• 238000003199 nucleic acid amplification method Methods 0.000 claims description 26
• 102100039065 Interleukin-1 beta Human genes 0.000 claims description 25
• 239000005557 antagonist Substances 0.000 claims description 25
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 21
• 238000011161 development Methods 0.000 claims description 19
• 230000001965 increasing effect Effects 0.000 claims description 18
• 230000001225 therapeutic effect Effects 0.000 claims description 17
• 239000000556 agonist Substances 0.000 claims description 14
• 238000012163 sequencing technique Methods 0.000 claims description 10
• 101710163270 Nuclease Proteins 0.000 claims description 5
• 230000029087 digestion Effects 0.000 claims description 5
• 108091008146 restriction endonucleases Proteins 0.000 claims description 5
• 102100020881 Interleukin-1 alpha Human genes 0.000 claims description 3
• 102000015696 Interleukins Human genes 0.000 claims description 3
• 108010063738 Interleukins Proteins 0.000 claims description 3
• 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 claims 2
• 238000001976 enzyme digestion Methods 0.000 claims 2
• 101150076489 B gene Proteins 0.000 claims 1
• 108090000623 proteins and genes Proteins 0.000 description 181
• 102000004169 proteins and genes Human genes 0.000 description 90
• 210000004027 cell Anatomy 0.000 description 72
• 102000053602 DNA Human genes 0.000 description 60
• 108020004414 DNA Proteins 0.000 description 60
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 56
• 208000015181 infectious disease Diseases 0.000 description 53
• 150000001875 compounds Chemical class 0.000 description 52
• 108700019146 Transgenes Proteins 0.000 description 50
• 201000010099 disease Diseases 0.000 description 49
• 210000001519 tissue Anatomy 0.000 description 44
• 230000035772 mutation Effects 0.000 description 43
• 239000000523 sample Substances 0.000 description 43
• 241001465754 Metazoa Species 0.000 description 41
• 230000014509 gene expression Effects 0.000 description 38
• 239000000047 product Substances 0.000 description 34
• 125000003729 nucleotide group Chemical group 0.000 description 33
• 102000005962 receptors Human genes 0.000 description 33
• 108020003175 receptors Proteins 0.000 description 33
• 239000013615 primer Substances 0.000 description 31
• 239000002773 nucleotide Substances 0.000 description 30
• 230000004044 response Effects 0.000 description 30
• 238000012360 testing method Methods 0.000 description 30
• 230000009261 transgenic effect Effects 0.000 description 30
• 230000002068 genetic effect Effects 0.000 description 28
• 108090000765 processed proteins & peptides Proteins 0.000 description 27
• 102000004127 Cytokines Human genes 0.000 description 26
• 108090000695 Cytokines Proteins 0.000 description 26
• 230000028709 inflammatory response Effects 0.000 description 25
• 208000014674 injury Diseases 0.000 description 25
• 238000003752 polymerase chain reaction Methods 0.000 description 24
• 102000054765 polymorphisms of proteins Human genes 0.000 description 24
• 239000003795 chemical substances by application Substances 0.000 description 23
• 102000004196 processed proteins & peptides Human genes 0.000 description 23
• 230000009885 systemic effect Effects 0.000 description 23
• 239000012634 fragment Substances 0.000 description 22
• 208000027418 Wounds and injury Diseases 0.000 description 21
• 102000054766 genetic haplotypes Human genes 0.000 description 21
• 229920001184 polypeptide Polymers 0.000 description 21
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 20
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 20
• 230000006378 damage Effects 0.000 description 20
• 210000000440 neutrophil Anatomy 0.000 description 19
• 230000000295 complement effect Effects 0.000 description 18
• 239000000203 mixture Substances 0.000 description 18
• 230000006798 recombination Effects 0.000 description 16
• 206010040070 Septic Shock Diseases 0.000 description 15
• 108020004999 messenger RNA Proteins 0.000 description 15
• 230000001105 regulatory effect Effects 0.000 description 15
• 229920002477 rna polymer Polymers 0.000 description 15
• 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 14
• 230000035939 shock Effects 0.000 description 14
• -1 superoxide anions Chemical class 0.000 description 14
• 230000003993 interaction Effects 0.000 description 13
• 210000002540 macrophage Anatomy 0.000 description 13
• 206010061218 Inflammation Diseases 0.000 description 12
• 108091028043 Nucleic acid sequence Proteins 0.000 description 12
• 238000006243 chemical reaction Methods 0.000 description 12
• 230000004054 inflammatory process Effects 0.000 description 12
• 244000005700 microbiome Species 0.000 description 12
• 238000005215 recombination Methods 0.000 description 12
• 230000036303 septic shock Effects 0.000 description 12
• 102000004190 Enzymes Human genes 0.000 description 11
• 108090000790 Enzymes Proteins 0.000 description 11
• 230000015572 biosynthetic process Effects 0.000 description 11
• 210000000349 chromosome Anatomy 0.000 description 11
• 239000002158 endotoxin Substances 0.000 description 11
• 229940088598 enzyme Drugs 0.000 description 11
• 230000002757 inflammatory effect Effects 0.000 description 11
• 210000001161 mammalian embryo Anatomy 0.000 description 11
• 230000000813 microbial effect Effects 0.000 description 11
• 230000014616 translation Effects 0.000 description 11
• 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 10
• 210000004369 blood Anatomy 0.000 description 10
• 239000008280 blood Substances 0.000 description 10
• 229940079593 drug Drugs 0.000 description 10
• 230000006870 function Effects 0.000 description 10
• 238000000338 in vitro Methods 0.000 description 10
• 230000004913 activation Effects 0.000 description 9
• 230000002759 chromosomal effect Effects 0.000 description 9
• 238000003776 cleavage reaction Methods 0.000 description 9
• 230000007123 defense Effects 0.000 description 9
• 230000007246 mechanism Effects 0.000 description 9
• 108010051219 Cre recombinase Proteins 0.000 description 8
• 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 8
• 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 8
• 230000001413 cellular effect Effects 0.000 description 8
• 108091008053 gene clusters Proteins 0.000 description 8
• 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 8
• 238000004519 manufacturing process Methods 0.000 description 8
• 210000004940 nucleus Anatomy 0.000 description 8
• 230000007017 scission Effects 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• 238000013519 translation Methods 0.000 description 8
• 238000011282 treatment Methods 0.000 description 8
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 7
• 102000004889 Interleukin-6 Human genes 0.000 description 7
• 108090001005 Interleukin-6 Proteins 0.000 description 7
• 238000012408 PCR amplification Methods 0.000 description 7
• 230000004075 alteration Effects 0.000 description 7
• 230000008901 benefit Effects 0.000 description 7
• 230000008859 change Effects 0.000 description 7
• 230000034994 death Effects 0.000 description 7
• 208000035475 disorder Diseases 0.000 description 7
• 238000002347 injection Methods 0.000 description 7
• 239000007924 injection Substances 0.000 description 7
• 230000009545 invasion Effects 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 210000000056 organ Anatomy 0.000 description 7
• 230000008569 process Effects 0.000 description 7
• 241000894007 species Species 0.000 description 7
• 230000008733 trauma Effects 0.000 description 7
• 239000013598 vector Substances 0.000 description 7
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
• 241000894006 Bacteria Species 0.000 description 6
• 108010037462 Cyclooxygenase 2 Proteins 0.000 description 6
• 102100037852 Insulin-like growth factor I Human genes 0.000 description 6
• 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 6
• 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 6
• 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 6
• 108010091086 Recombinases Proteins 0.000 description 6
• 102000018120 Recombinases Human genes 0.000 description 6
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 6
• 230000001594 aberrant effect Effects 0.000 description 6
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 6
• 230000000692 anti-sense effect Effects 0.000 description 6
• 230000004087 circulation Effects 0.000 description 6
• 239000013068 control sample Substances 0.000 description 6
• 230000003247 decreasing effect Effects 0.000 description 6
• 238000009472 formulation Methods 0.000 description 6
• 210000003917 human chromosome Anatomy 0.000 description 6
• 230000037230 mobility Effects 0.000 description 6
• 239000001301 oxygen Substances 0.000 description 6
• 229910052760 oxygen Inorganic materials 0.000 description 6
• 244000052769 pathogen Species 0.000 description 6
• 238000012216 screening Methods 0.000 description 6
• 210000002966 serum Anatomy 0.000 description 6
• 230000019491 signal transduction Effects 0.000 description 6
• 150000003384 small molecules Chemical class 0.000 description 6
• 238000002560 therapeutic procedure Methods 0.000 description 6
• 230000007923 virulence factor Effects 0.000 description 6
• 239000000304 virulence factor Substances 0.000 description 6
• 108060002716 Exonuclease Proteins 0.000 description 5
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
• 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 5
• 102000003777 Interleukin-1 beta Human genes 0.000 description 5
• 108090000193 Interleukin-1 beta Proteins 0.000 description 5
• 108050006617 Interleukin-1 receptor Proteins 0.000 description 5
• 208000010718 Multiple Organ Failure Diseases 0.000 description 5
• 230000003213 activating effect Effects 0.000 description 5
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 5
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
• 230000001580 bacterial effect Effects 0.000 description 5
• 230000000875 corresponding effect Effects 0.000 description 5
• 210000002257 embryonic structure Anatomy 0.000 description 5
• 102000013165 exonuclease Human genes 0.000 description 5
• 238000003205 genotyping method Methods 0.000 description 5
• 239000003112 inhibitor Substances 0.000 description 5
• 208000028867 ischemia Diseases 0.000 description 5
• 238000000520 microinjection Methods 0.000 description 5
• 210000001616 monocyte Anatomy 0.000 description 5
• 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 5
• 230000026731 phosphorylation Effects 0.000 description 5
• 238000006366 phosphorylation reaction Methods 0.000 description 5
• 238000003757 reverse transcription PCR Methods 0.000 description 5
• 230000028327 secretion Effects 0.000 description 5
• 230000008718 systemic inflammatory response Effects 0.000 description 5
• 230000002103 transcriptional effect Effects 0.000 description 5
• 102000008186 Collagen Human genes 0.000 description 4
• 108010035532 Collagen Proteins 0.000 description 4
• 108010000912 Egg Proteins Proteins 0.000 description 4
• 102000002322 Egg Proteins Human genes 0.000 description 4
• 108010049003 Fibrinogen Proteins 0.000 description 4
• 102000008946 Fibrinogen Human genes 0.000 description 4
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
• 102000019223 Interleukin-1 receptor Human genes 0.000 description 4
• 108010002350 Interleukin-2 Proteins 0.000 description 4
• 102000000588 Interleukin-2 Human genes 0.000 description 4
• 108090000978 Interleukin-4 Proteins 0.000 description 4
• 102100037611 Lysophospholipase Human genes 0.000 description 4
• 241000124008 Mammalia Species 0.000 description 4
• 201000009906 Meningitis Diseases 0.000 description 4
• 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 4
• 108050006599 Metalloproteinase inhibitor 1 Proteins 0.000 description 4
• 208000034486 Multi-organ failure Diseases 0.000 description 4
• 241000699666 Mus <mouse, genus> Species 0.000 description 4
• 206010028851 Necrosis Diseases 0.000 description 4
• 108010058864 Phospholipases A2 Proteins 0.000 description 4
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
• 206010035664 Pneumonia Diseases 0.000 description 4
• 206010037660 Pyrexia Diseases 0.000 description 4
• 241000700605 Viruses Species 0.000 description 4
• 108010093894 Xanthine oxidase Proteins 0.000 description 4
• 239000002253 acid Substances 0.000 description 4
• 238000010171 animal model Methods 0.000 description 4
• 239000011324 bead Substances 0.000 description 4
• 230000033228 biological regulation Effects 0.000 description 4
• 238000004113 cell culture Methods 0.000 description 4
• 210000000170 cell membrane Anatomy 0.000 description 4
• 229920001436 collagen Polymers 0.000 description 4
• 230000024203 complement activation Effects 0.000 description 4
• 238000012217 deletion Methods 0.000 description 4
• 230000037430 deletion Effects 0.000 description 4
• XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 4
• 229940000406 drug candidate Drugs 0.000 description 4
• 230000003511 endothelial effect Effects 0.000 description 4
• 238000005516 engineering process Methods 0.000 description 4
• 229940012952 fibrinogen Drugs 0.000 description 4
• 239000000499 gel Substances 0.000 description 4
• 210000004602 germ cell Anatomy 0.000 description 4
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
• 238000010348 incorporation Methods 0.000 description 4
• 238000011534 incubation Methods 0.000 description 4
• 230000002458 infectious effect Effects 0.000 description 4
• 208000027866 inflammatory disease Diseases 0.000 description 4
• 238000003780 insertion Methods 0.000 description 4
• 230000037431 insertion Effects 0.000 description 4
• 230000002427 irreversible effect Effects 0.000 description 4
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
• 239000003446 ligand Substances 0.000 description 4
• 238000007834 ligase chain reaction Methods 0.000 description 4
• 239000011159 matrix material Substances 0.000 description 4
• 230000001404 mediated effect Effects 0.000 description 4
• 210000004379 membrane Anatomy 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 230000017074 necrotic cell death Effects 0.000 description 4
• 230000001338 necrotic effect Effects 0.000 description 4
• 210000004681 ovum Anatomy 0.000 description 4
• 230000010412 perfusion Effects 0.000 description 4
• 230000036470 plasma concentration Effects 0.000 description 4
• 238000002360 preparation method Methods 0.000 description 4
• 230000000770 proinflammatory effect Effects 0.000 description 4
• 229940044551 receptor antagonist Drugs 0.000 description 4
• 239000002464 receptor antagonist Substances 0.000 description 4
• 150000003839 salts Chemical class 0.000 description 4
• 210000000130 stem cell Anatomy 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 230000002459 sustained effect Effects 0.000 description 4
• 208000024891 symptom Diseases 0.000 description 4
• 208000011580 syndromic disease Diseases 0.000 description 4
• 238000013518 transcription Methods 0.000 description 4
• LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 3
• 206010058040 Abdominal sepsis Diseases 0.000 description 3
• 208000024172 Cardiovascular disease Diseases 0.000 description 3
• 239000003155 DNA primer Substances 0.000 description 3
• 241000588724 Escherichia coli Species 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 102000013462 Interleukin-12 Human genes 0.000 description 3
• 108010065805 Interleukin-12 Proteins 0.000 description 3
• 108010002386 Interleukin-3 Proteins 0.000 description 3
• 102000000646 Interleukin-3 Human genes 0.000 description 3
• 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 3
• 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 3
• 108091092878 Microsatellite Proteins 0.000 description 3
• 206010061308 Neonatal infection Diseases 0.000 description 3
• 108010067372 Pancreatic elastase Proteins 0.000 description 3
• 102000016387 Pancreatic elastase Human genes 0.000 description 3
• 108091093037 Peptide nucleic acid Proteins 0.000 description 3
• 102000001253 Protein Kinase Human genes 0.000 description 3
• 108090000315 Protein Kinase C Proteins 0.000 description 3
• 102000003923 Protein Kinase C Human genes 0.000 description 3
• 230000010799 Receptor Interactions Effects 0.000 description 3
• 108020004511 Recombinant DNA Proteins 0.000 description 3
• 206010038997 Retroviral infections Diseases 0.000 description 3
• 206010053879 Sepsis syndrome Diseases 0.000 description 3
• 102000019197 Superoxide Dismutase Human genes 0.000 description 3
• 108010012715 Superoxide dismutase Proteins 0.000 description 3
• 108090000190 Thrombin Proteins 0.000 description 3
• 208000007536 Thrombosis Diseases 0.000 description 3
• 206010052428 Wound Diseases 0.000 description 3
• 230000002159 abnormal effect Effects 0.000 description 3
• 230000005856 abnormality Effects 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 239000003242 anti bacterial agent Substances 0.000 description 3
• 229940088710 antibiotic agent Drugs 0.000 description 3
• 230000003115 biocidal effect Effects 0.000 description 3
• 230000004071 biological effect Effects 0.000 description 3
• 229960002685 biotin Drugs 0.000 description 3
• 235000020958 biotin Nutrition 0.000 description 3
• 239000011616 biotin Substances 0.000 description 3
• 210000002459 blastocyst Anatomy 0.000 description 3
• 210000001109 blastomere Anatomy 0.000 description 3
• 230000000747 cardiac effect Effects 0.000 description 3
• 238000010367 cloning Methods 0.000 description 3
• 230000015271 coagulation Effects 0.000 description 3
• 238000005345 coagulation Methods 0.000 description 3
• 239000002299 complementary DNA Substances 0.000 description 3
• 238000011109 contamination Methods 0.000 description 3
• 230000007423 decrease Effects 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 238000013461 design Methods 0.000 description 3
• 229960002986 dinoprostone Drugs 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 150000002066 eicosanoids Chemical class 0.000 description 3
• 238000011156 evaluation Methods 0.000 description 3
• 239000013604 expression vector Substances 0.000 description 3
• 230000004720 fertilization Effects 0.000 description 3
• 210000002950 fibroblast Anatomy 0.000 description 3
• 230000009395 genetic defect Effects 0.000 description 3
• 238000010353 genetic engineering Methods 0.000 description 3
• 239000003102 growth factor Substances 0.000 description 3
• 230000000004 hemodynamic effect Effects 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 230000000977 initiatory effect Effects 0.000 description 3
• 238000002372 labelling Methods 0.000 description 3
• 229920006008 lipopolysaccharide Polymers 0.000 description 3
• 230000033001 locomotion Effects 0.000 description 3
• 238000009593 lumbar puncture Methods 0.000 description 3
• 238000002844 melting Methods 0.000 description 3
• 230000002503 metabolic effect Effects 0.000 description 3
• 239000004005 microsphere Substances 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 210000001539 phagocyte Anatomy 0.000 description 3
• 239000013612 plasmid Substances 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 239000002243 precursor Substances 0.000 description 3
• 230000000750 progressive effect Effects 0.000 description 3
• 230000002035 prolonged effect Effects 0.000 description 3
• XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 3
• 108060006633 protein kinase Proteins 0.000 description 3
• 239000011541 reaction mixture Substances 0.000 description 3
• 230000010076 replication Effects 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• 208000013223 septicemia Diseases 0.000 description 3
• 239000007790 solid phase Substances 0.000 description 3
• 150000003431 steroids Chemical class 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 229960004072 thrombin Drugs 0.000 description 3
• DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 3
• 231100000331 toxic Toxicity 0.000 description 3
• 230000002588 toxic effect Effects 0.000 description 3
• 230000035897 transcription Effects 0.000 description 3
• 230000002463 transducing effect Effects 0.000 description 3
• 208000019553 vascular disease Diseases 0.000 description 3
• 230000008728 vascular permeability Effects 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• 230000029663 wound healing Effects 0.000 description 3
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
• HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
• VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 2
• 108010005094 Advanced Glycation End Products Proteins 0.000 description 2
• 206010059245 Angiopathy Diseases 0.000 description 2
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
• 102000007592 Apolipoproteins Human genes 0.000 description 2
• 108010071619 Apolipoproteins Proteins 0.000 description 2
• 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 2
• 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 2
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
• 108090001008 Avidin Proteins 0.000 description 2
• 208000031729 Bacteremia Diseases 0.000 description 2
• 238000011740 C57BL/6 mouse Methods 0.000 description 2
• 102100032912 CD44 antigen Human genes 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 108090000994 Catalytic RNA Proteins 0.000 description 2
• 102000053642 Catalytic RNA Human genes 0.000 description 2
• 108010075016 Ceruloplasmin Proteins 0.000 description 2
• 102100023321 Ceruloplasmin Human genes 0.000 description 2
• 206010009900 Colitis ulcerative Diseases 0.000 description 2
• 102000029816 Collagenase Human genes 0.000 description 2
• 108060005980 Collagenase Proteins 0.000 description 2
• 108020004635 Complementary DNA Proteins 0.000 description 2
• 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 2
• 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 2
• 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
• 229920000742 Cotton Polymers 0.000 description 2
• 206010050685 Cytokine storm Diseases 0.000 description 2
• 102000004237 Decorin Human genes 0.000 description 2
• 108090000738 Decorin Proteins 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• 108010024212 E-Selectin Proteins 0.000 description 2
• 102100023471 E-selectin Human genes 0.000 description 2
• 208000037487 Endotoxemia Diseases 0.000 description 2
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
• 108091029865 Exogenous DNA Proteins 0.000 description 2
• 108010046276 FLP recombinase Proteins 0.000 description 2
• 102000009123 Fibrin Human genes 0.000 description 2
• 108010073385 Fibrin Proteins 0.000 description 2
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
• 108010012088 Fibrinogen Receptors Proteins 0.000 description 2
• 108091006027 G proteins Proteins 0.000 description 2
• 102000030782 GTP binding Human genes 0.000 description 2
• 108091000058 GTP-Binding Proteins 0.000 description 2
• 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 2
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
• 102100033299 Glia-derived nexin Human genes 0.000 description 2
• 101710183811 Glia-derived nexin Proteins 0.000 description 2
• 108010024636 Glutathione Proteins 0.000 description 2
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
• 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 2
• 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 2
• 102100034221 Growth-regulated alpha protein Human genes 0.000 description 2
• 102000016761 Haem oxygenases Human genes 0.000 description 2
• 108050006318 Haem oxygenases Proteins 0.000 description 2
• 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
• 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
• 108091027305 Heteroduplex Proteins 0.000 description 2
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
• 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 2
• 101000998122 Homo sapiens Interleukin-37 Proteins 0.000 description 2
• 101000622137 Homo sapiens P-selectin Proteins 0.000 description 2
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
• 208000001953 Hypotension Diseases 0.000 description 2
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
• 102100026017 Interleukin-1 receptor type 2 Human genes 0.000 description 2
• 101710149731 Interleukin-1 receptor type 2 Proteins 0.000 description 2
• 108090000174 Interleukin-10 Proteins 0.000 description 2
• 108090000176 Interleukin-13 Proteins 0.000 description 2
• 102000010789 Interleukin-2 Receptors Human genes 0.000 description 2
• 108010038453 Interleukin-2 Receptors Proteins 0.000 description 2
• 102000010790 Interleukin-3 Receptors Human genes 0.000 description 2
• 108010038452 Interleukin-3 Receptors Proteins 0.000 description 2
• 102100033502 Interleukin-37 Human genes 0.000 description 2
• 102000010786 Interleukin-5 Receptors Human genes 0.000 description 2
• 108010038484 Interleukin-5 Receptors Proteins 0.000 description 2
• 108091092195 Intron Proteins 0.000 description 2
• 108010092694 L-Selectin Proteins 0.000 description 2
• 102100033467 L-selectin Human genes 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 102000003960 Ligases Human genes 0.000 description 2
• 108090000364 Ligases Proteins 0.000 description 2
• 208000032376 Lung infection Diseases 0.000 description 2
• WCERJEZPIONOJU-LHEXPUQLSA-N Magnosalin Chemical compound C1=C(OC)C(OC)=CC(OC)=C1[C@H]1[C@H](C=2C(=CC(OC)=C(OC)C=2)OC)[C@H](C)[C@H]1C WCERJEZPIONOJU-LHEXPUQLSA-N 0.000 description 2
• 102000003792 Metallothionein Human genes 0.000 description 2
• 108090000157 Metallothionein Proteins 0.000 description 2
• 102000016943 Muramidase Human genes 0.000 description 2
• 108010014251 Muramidase Proteins 0.000 description 2
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
• 208000006816 Neonatal Sepsis Diseases 0.000 description 2
• 238000000636 Northern blotting Methods 0.000 description 2
• 206010053159 Organ failure Diseases 0.000 description 2
• 102100023472 P-selectin Human genes 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 206010057249 Phagocytosis Diseases 0.000 description 2
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
• 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 description 2
• 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
• 102000004179 Plasminogen Activator Inhibitor 2 Human genes 0.000 description 2
• 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 description 2
• 108010003541 Platelet Activating Factor Proteins 0.000 description 2
• 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 description 2
• 101710103506 Platelet-derived growth factor subunit A Proteins 0.000 description 2
• 102100020847 Protein FosB Human genes 0.000 description 2
• 108010029485 Protein Isoforms Proteins 0.000 description 2
• 102000001708 Protein Isoforms Human genes 0.000 description 2
• 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
• 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
• 201000004681 Psoriasis Diseases 0.000 description 2
• REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 208000004756 Respiratory Insufficiency Diseases 0.000 description 2
• 241000219061 Rheum Species 0.000 description 2
• 102100037599 SPARC Human genes 0.000 description 2
• 101710100111 SPARC Proteins 0.000 description 2
• 101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 2
• 108700028909 Serum Amyloid A Proteins 0.000 description 2
• 102000054727 Serum Amyloid A Human genes 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• 108010090804 Streptavidin Proteins 0.000 description 2
• 206010048960 Streptococcal sepsis Diseases 0.000 description 2
• 102100030416 Stromelysin-1 Human genes 0.000 description 2
• 101710108790 Stromelysin-1 Proteins 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 108010018242 Transcription Factor AP-1 Proteins 0.000 description 2
• 101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 2
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 description 2
• 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
• 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
• 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
• 102000005773 Xanthine dehydrogenase Human genes 0.000 description 2
• 108010091383 Xanthine dehydrogenase Proteins 0.000 description 2
• 102100033220 Xanthine oxidase Human genes 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 108010023082 activin A Proteins 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 150000001413 amino acids Chemical group 0.000 description 2
• 230000003042 antagnostic effect Effects 0.000 description 2
• 230000003466 anti-cipated effect Effects 0.000 description 2
• 230000003110 anti-inflammatory effect Effects 0.000 description 2
• 239000000427 antigen Substances 0.000 description 2
• 230000000890 antigenic effect Effects 0.000 description 2
• 108091007433 antigens Proteins 0.000 description 2
• 102000036639 antigens Human genes 0.000 description 2
• 239000000074 antisense oligonucleotide Substances 0.000 description 2
• 238000012230 antisense oligonucleotides Methods 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 206010003246 arthritis Diseases 0.000 description 2
• 230000003305 autocrine Effects 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 230000000975 bioactive effect Effects 0.000 description 2
• 210000000601 blood cell Anatomy 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 230000009918 complex formation Effects 0.000 description 2
• 238000010276 construction Methods 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 206010052015 cytokine release syndrome Diseases 0.000 description 2
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
• 230000007547 defect Effects 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 2
• 230000001066 destructive effect Effects 0.000 description 2
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
• 229960003957 dexamethasone Drugs 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 238000002405 diagnostic procedure Methods 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 208000009190 disseminated intravascular coagulation Diseases 0.000 description 2
• 239000012636 effector Substances 0.000 description 2
• 235000013601 eggs Nutrition 0.000 description 2
• 238000001962 electrophoresis Methods 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 210000002889 endothelial cell Anatomy 0.000 description 2
• 210000003038 endothelium Anatomy 0.000 description 2
• 230000007613 environmental effect Effects 0.000 description 2
• 229950003499 fibrin Drugs 0.000 description 2
• 108020001507 fusion proteins Proteins 0.000 description 2
• 102000037865 fusion proteins Human genes 0.000 description 2
• 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 2
• 238000010448 genetic screening Methods 0.000 description 2
• 229960003180 glutathione Drugs 0.000 description 2
• 230000009097 homeostatic mechanism Effects 0.000 description 2
• 230000006801 homologous recombination Effects 0.000 description 2
• 238000002744 homologous recombination Methods 0.000 description 2
• 230000036543 hypotension Effects 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 238000007901 in situ hybridization Methods 0.000 description 2
• 238000011065 in-situ storage Methods 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 230000003960 inflammatory cascade Effects 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• 230000018276 interleukin-1 production Effects 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 230000002147 killing effect Effects 0.000 description 2
• 239000004310 lactic acid Substances 0.000 description 2
• 235000014655 lactic acid Nutrition 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• 210000000265 leukocyte Anatomy 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 235000010335 lysozyme Nutrition 0.000 description 2
• 239000004325 lysozyme Substances 0.000 description 2
• 229960000274 lysozyme Drugs 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 230000013011 mating Effects 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• 230000008018 melting Effects 0.000 description 2
• 208000037941 meningococcal disease Diseases 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 230000004089 microcirculation Effects 0.000 description 2
• 210000004088 microvessel Anatomy 0.000 description 2
• 230000033607 mismatch repair Effects 0.000 description 2
• 239000003226 mitogen Substances 0.000 description 2
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
• 230000000869 mutational effect Effects 0.000 description 2
• 238000007857 nested PCR Methods 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 239000012285 osmium tetroxide Substances 0.000 description 2
• 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
• 230000003076 paracrine Effects 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 239000000816 peptidomimetic Substances 0.000 description 2
• 230000036513 peripheral conductance Effects 0.000 description 2
• 230000008782 phagocytosis Effects 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 230000002974 pharmacogenomic effect Effects 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• 239000002797 plasminogen activator inhibitor Substances 0.000 description 2
• 229920002401 polyacrylamide Polymers 0.000 description 2
• 230000003234 polygenic effect Effects 0.000 description 2
• 102000040430 polynucleotide Human genes 0.000 description 2
• 108091033319 polynucleotide Proteins 0.000 description 2
• 239000002157 polynucleotide Substances 0.000 description 2
• 238000010837 poor prognosis Methods 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 230000002028 premature Effects 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 230000002250 progressing effect Effects 0.000 description 2
• 238000001243 protein synthesis Methods 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 108091092562 ribozyme Proteins 0.000 description 2
• 101150076141 rn gene Proteins 0.000 description 2
• 231100000241 scar Toxicity 0.000 description 2
• 238000007423 screening assay Methods 0.000 description 2
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 230000006641 stabilisation Effects 0.000 description 2
• 238000011105 stabilization Methods 0.000 description 2
• 230000035882 stress Effects 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 238000007910 systemic administration Methods 0.000 description 2
• ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
• 230000000451 tissue damage Effects 0.000 description 2
• 231100000827 tissue damage Toxicity 0.000 description 2
• 208000037816 tissue injury Diseases 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
• 239000002753 trypsin inhibitor Substances 0.000 description 2
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 241001430294 unidentified retrovirus Species 0.000 description 2
• 229960005356 urokinase Drugs 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 230000001018 virulence Effects 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
• XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
• IESDGNYHXIOKRW-YXMSTPNBSA-N (2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-YXMSTPNBSA-N 0.000 description 1
• ZAQVQQDAYHGEBE-MMJJMRCTSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 ZAQVQQDAYHGEBE-MMJJMRCTSA-N 0.000 description 1
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
• 101150084750 1 gene Proteins 0.000 description 1
• DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
• ZHXUEUKVDMWSKV-UHFFFAOYSA-N 1-(3,5-ditert-butyl-4-hydroxyphenyl)hex-5-yn-1-one Chemical compound CC(C)(C)C1=CC(C(=O)CCCC#C)=CC(C(C)(C)C)=C1O ZHXUEUKVDMWSKV-UHFFFAOYSA-N 0.000 description 1
• KCPHXRBKBLJJJJ-UHFFFAOYSA-N 1-[7-(4-fluorophenyl)-8-pyridin-4-yl-3,4-dihydro-1H-pyrazolo[5,1-c][1,2,4]triazin-2-yl]-2-phenylethane-1,2-dione sulfuric acid Chemical class OS(O)(=O)=O.Fc1ccc(cc1)-c1nn2CCN(Nc2c1-c1ccncc1)C(=O)C(=O)c1ccccc1 KCPHXRBKBLJJJJ-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• VKEZHJDNMGHHKH-UHFFFAOYSA-N 13-hydroxyoctadec-2-enoic acid Chemical compound CCCCCC(O)CCCCCCCCCC=CC(O)=O VKEZHJDNMGHHKH-UHFFFAOYSA-N 0.000 description 1
• TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 description 1
• NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
• LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
• 239000005541 ACE inhibitor Substances 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 206010048998 Acute phase reaction Diseases 0.000 description 1
• 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
• 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
• 229930195730 Aflatoxin Natural products 0.000 description 1
• XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
• 101100397594 Ancylostoma caninum JNK-1 gene Proteins 0.000 description 1
• 102400000345 Angiotensin-2 Human genes 0.000 description 1
• 101800000733 Angiotensin-2 Proteins 0.000 description 1
• 108020005544 Antisense RNA Proteins 0.000 description 1
• 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 1
• 206010003598 Atelectasis Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 208000037157 Azotemia Diseases 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 229940123031 Beta adrenoreceptor agonist Drugs 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 241000421809 Brisaster fragilis Species 0.000 description 1
• KBGVXGCSWQCJJX-UHFFFAOYSA-N CCCCCCCCCC(O)CCCCCC=CC(O)=O Chemical compound CCCCCCCCCC(O)CCCCCC=CC(O)=O KBGVXGCSWQCJJX-UHFFFAOYSA-N 0.000 description 1
• 108010084313 CD58 Antigens Proteins 0.000 description 1
• 229940124638 COX inhibitor Drugs 0.000 description 1
• 101100505076 Caenorhabditis elegans gly-2 gene Proteins 0.000 description 1
• 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 102000004031 Carboxy-Lyases Human genes 0.000 description 1
• 108090000489 Carboxy-Lyases Proteins 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 102100035882 Catalase Human genes 0.000 description 1
• 108010053835 Catalase Proteins 0.000 description 1
• 206010007882 Cellulitis Diseases 0.000 description 1
• 108090000227 Chymases Proteins 0.000 description 1
• 102000003858 Chymases Human genes 0.000 description 1
• 108090000317 Chymotrypsin Proteins 0.000 description 1
• 206010009192 Circulatory collapse Diseases 0.000 description 1
• 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
• 108010065152 Coagulase Proteins 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 208000003322 Coinfection Diseases 0.000 description 1
• 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
• 108010078546 Complement C5a Proteins 0.000 description 1
• 102000016550 Complement Factor H Human genes 0.000 description 1
• 108010053085 Complement Factor H Proteins 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 241000557626 Corvus corax Species 0.000 description 1
• 108020001738 DNA Glycosylase Proteins 0.000 description 1
• 108020003215 DNA Probes Proteins 0.000 description 1
• 102000028381 DNA glycosylase Human genes 0.000 description 1
• 239000003298 DNA probe Substances 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
• 206010014824 Endotoxic shock Diseases 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 241000702191 Escherichia virus P1 Species 0.000 description 1
• WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• 206010053172 Fatal outcomes Diseases 0.000 description 1
• 208000037194 Fever of Unknown Origin Diseases 0.000 description 1
• 108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 description 1
• 108010088842 Fibrinolysin Proteins 0.000 description 1
• 241000192125 Firmicutes Species 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
• 102000006395 Globulins Human genes 0.000 description 1
• 108010044091 Globulins Proteins 0.000 description 1
• 102400000326 Glucagon-like peptide 2 Human genes 0.000 description 1
• 101800000221 Glucagon-like peptide 2 Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 102000005720 Glutathione transferase Human genes 0.000 description 1
• 108010070675 Glutathione transferase Proteins 0.000 description 1
• 208000003807 Graves Disease Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 102000006354 HLA-DR Antigens Human genes 0.000 description 1
• 108010058597 HLA-DR Antigens Proteins 0.000 description 1
• 239000012981 Hank's balanced salt solution Substances 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 206010019663 Hepatic failure Diseases 0.000 description 1
• WCERJEZPIONOJU-UHFFFAOYSA-N Heterotropan Natural products C1=C(OC)C(OC)=CC(OC)=C1C1C(C=2C(=CC(OC)=C(OC)C=2)OC)C(C)C1C WCERJEZPIONOJU-UHFFFAOYSA-N 0.000 description 1
• 102000006947 Histones Human genes 0.000 description 1
• 108010033040 Histones Proteins 0.000 description 1
• 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 206010058490 Hyperoxia Diseases 0.000 description 1
• 206010058558 Hypoperfusion Diseases 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
• 102100025390 Integrin beta-2 Human genes 0.000 description 1
• 102100040018 Interferon alpha-2 Human genes 0.000 description 1
• 108010079944 Interferon-alpha2b Proteins 0.000 description 1
• 102000003996 Interferon-beta Human genes 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• 108010082786 Interleukin-1alpha Proteins 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 206010022941 Iridocyclitis Diseases 0.000 description 1
• 208000003456 Juvenile Arthritis Diseases 0.000 description 1
• 108010093008 Kinins Proteins 0.000 description 1
• 102000002397 Kinins Human genes 0.000 description 1
• PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
• 208000034693 Laceration Diseases 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 102000016267 Leptin Human genes 0.000 description 1
• 108010092277 Leptin Proteins 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 108010014603 Leukocidins Proteins 0.000 description 1
• 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
• 241000186781 Listeria Species 0.000 description 1
• 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
• 235000019759 Maize starch Nutrition 0.000 description 1
• YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 208000036626 Mental retardation Diseases 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 102000029749 Microtubule Human genes 0.000 description 1
• 108091022875 Microtubule Proteins 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 102000008934 Muscle Proteins Human genes 0.000 description 1
• 108010074084 Muscle Proteins Proteins 0.000 description 1
• 108010021466 Mutant Proteins Proteins 0.000 description 1
• 102000008300 Mutant Proteins Human genes 0.000 description 1
• 241000588653 Neisseria Species 0.000 description 1
• 241001045988 Neogene Species 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 244000061176 Nicotiana tabacum Species 0.000 description 1
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
• 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
• 108700022034 Opsonin Proteins Proteins 0.000 description 1
• 102100021079 Ornithine decarboxylase Human genes 0.000 description 1
• 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 102100034574 P protein Human genes 0.000 description 1
• 101710181008 P protein Proteins 0.000 description 1
• 239000012807 PCR reagent Substances 0.000 description 1
• 206010033645 Pancreatitis Diseases 0.000 description 1
• 206010033647 Pancreatitis acute Diseases 0.000 description 1
• 241000282320 Panthera leo Species 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 208000037581 Persistent Infection Diseases 0.000 description 1
• 102100029251 Phagocytosis-stimulating peptide Human genes 0.000 description 1
• 108010010677 Phosphodiesterase I Proteins 0.000 description 1
• 101710177166 Phosphoprotein Proteins 0.000 description 1
• 108010047620 Phytohemagglutinins Proteins 0.000 description 1
• 108700023400 Platelet-activating factor receptors Proteins 0.000 description 1
• 102000007327 Protamines Human genes 0.000 description 1
• 108010007568 Protamines Proteins 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
• 108010066717 Q beta Replicase Proteins 0.000 description 1
• ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
• 206010063837 Reperfusion injury Diseases 0.000 description 1
• 108700008625 Reporter Genes Proteins 0.000 description 1
• HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 241000225041 Roestes Species 0.000 description 1
• NGVMVBQRKZPFLB-YFKPBYRVSA-N S-methyl-L-thiocitrulline Chemical compound CSC(N)=NCCC[C@H](N)C(O)=O NGVMVBQRKZPFLB-YFKPBYRVSA-N 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• 108091081021 Sense strand Proteins 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 206010040049 Sepsis neonatal Diseases 0.000 description 1
• 206010049771 Shock haemorrhagic Diseases 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 238000002105 Southern blotting Methods 0.000 description 1
• 241000191967 Staphylococcus aureus Species 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 208000033809 Suppuration Diseases 0.000 description 1
• 108020005038 Terminator Codon Proteins 0.000 description 1
• 102100026966 Thrombomodulin Human genes 0.000 description 1
• 108010079274 Thrombomodulin Proteins 0.000 description 1
• 108020004440 Thymidine kinase Proteins 0.000 description 1
• 235000011941 Tilia x europaea Nutrition 0.000 description 1
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
• 206010044248 Toxic shock syndrome Diseases 0.000 description 1
• 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108010009583 Transforming Growth Factors Proteins 0.000 description 1
• 102000009618 Transforming Growth Factors Human genes 0.000 description 1
• XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
• 108010084754 Tuftsin Proteins 0.000 description 1
• 108010047933 Tumor Necrosis Factor alpha-Induced Protein 3 Proteins 0.000 description 1
• 102000007150 Tumor Necrosis Factor alpha-Induced Protein 3 Human genes 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
• TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
• 206010048709 Urosepsis Diseases 0.000 description 1
• 206010047139 Vasoconstriction Diseases 0.000 description 1
• 206010047141 Vasodilatation Diseases 0.000 description 1
• 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 241000269370 Xenopus <genus> Species 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• 206010000269 abscess Diseases 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 229960004308 acetylcysteine Drugs 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 208000038016 acute inflammation Diseases 0.000 description 1
• 230000006022 acute inflammation Effects 0.000 description 1
• 206010069351 acute lung injury Diseases 0.000 description 1
• 201000003229 acute pancreatitis Diseases 0.000 description 1
• 230000004658 acute-phase response Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 239000005409 aflatoxin Substances 0.000 description 1
• 238000011366 aggressive therapy Methods 0.000 description 1
• 230000001270 agonistic effect Effects 0.000 description 1
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
• 208000004631 alopecia areata Diseases 0.000 description 1
• 210000001132 alveolar macrophage Anatomy 0.000 description 1
• 229960005260 amiodarone Drugs 0.000 description 1
• 230000003322 aneuploid effect Effects 0.000 description 1
• 208000036878 aneuploidy Diseases 0.000 description 1
• 229950006323 angiotensin ii Drugs 0.000 description 1
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 230000001986 anti-endotoxic effect Effects 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• 238000003491 array Methods 0.000 description 1
• 238000010420 art technique Methods 0.000 description 1
• 238000003149 assay kit Methods 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• 239000003833 bile salt Substances 0.000 description 1
• 229940093761 bile salts Drugs 0.000 description 1
• 238000010256 biochemical assay Methods 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 238000010170 biological method Methods 0.000 description 1
• 230000008236 biological pathway Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 239000002981 blocking agent Substances 0.000 description 1
• 238000009640 blood culture Methods 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 239000000337 buffer salt Substances 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
• FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
• 229940043256 calcium pyrophosphate Drugs 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 229960004424 carbon dioxide Drugs 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000019522 cellular metabolic process Effects 0.000 description 1
• 210000003850 cellular structure Anatomy 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 210000002230 centromere Anatomy 0.000 description 1
• 239000012707 chemical precursor Substances 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 230000003399 chemotactic effect Effects 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 229960002376 chymotrypsin Drugs 0.000 description 1
• 229960001117 clenbuterol Drugs 0.000 description 1
• STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 229960001338 colchicine Drugs 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 230000001447 compensatory effect Effects 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 230000004154 complement system Effects 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 229940124446 critical care medicine Drugs 0.000 description 1
• 238000009402 cross-breeding Methods 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 230000001351 cycling effect Effects 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 229940104302 cytosine Drugs 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 230000004665 defense response Effects 0.000 description 1
• 239000003405 delayed action preparation Substances 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 239000003398 denaturant Substances 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 229960004590 diacerein Drugs 0.000 description 1
• 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
• 235000019700 dicalcium phosphate Nutrition 0.000 description 1
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
• 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
• 239000005546 dideoxynucleotide Substances 0.000 description 1
• 230000009699 differential effect Effects 0.000 description 1
• QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
• SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• 210000001840 diploid cell Anatomy 0.000 description 1
• 208000028659 discharge Diseases 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• 238000002224 dissection Methods 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000003532 endogenous pyrogen Substances 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 238000001952 enzyme assay Methods 0.000 description 1
• 210000002409 epiglottis Anatomy 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
• 229960003199 etacrynic acid Drugs 0.000 description 1
• 235000019441 ethanol Nutrition 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 229960004979 fampridine Drugs 0.000 description 1
• 239000003925 fat Substances 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 229960001022 fenoterol Drugs 0.000 description 1
• 210000003754 fetus Anatomy 0.000 description 1
• 239000000208 fibrin degradation product Substances 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000012224 gene deletion Methods 0.000 description 1
• 230000004077 genetic alteration Effects 0.000 description 1
• 231100000118 genetic alteration Toxicity 0.000 description 1
• 230000007614 genetic variation Effects 0.000 description 1
• TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 230000013595 glycosylation Effects 0.000 description 1
• 238000006206 glycosylation reaction Methods 0.000 description 1
• YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
• 230000036449 good health Effects 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 231100001261 hazardous Toxicity 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 230000002489 hematologic effect Effects 0.000 description 1
• 230000002008 hemorrhagic effect Effects 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 238000003268 heterogeneous phase assay Methods 0.000 description 1
• 208000021760 high fever Diseases 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 229960001340 histamine Drugs 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 102000057041 human TNF Human genes 0.000 description 1
• 229920002674 hyaluronan Polymers 0.000 description 1
• 229960003160 hyaluronic acid Drugs 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• QPCBNXNDVYOBIP-WHFBIAKZSA-N hymenialdisine Chemical compound NC1=NC(=O)C([C@@H]2[C@@H]3C=C(Br)N=C3C(=O)NCC2)=N1 QPCBNXNDVYOBIP-WHFBIAKZSA-N 0.000 description 1
• ATBAETXFFCOZOY-UHFFFAOYSA-N hymenialdisine Natural products N1C(N)=NC(=O)C1=C1C(C=C(Br)N2)=C2C(=O)NCC1 ATBAETXFFCOZOY-UHFFFAOYSA-N 0.000 description 1
• 230000000222 hyperoxic effect Effects 0.000 description 1
• 210000003016 hypothalamus Anatomy 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• 230000003100 immobilizing effect Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 238000010324 immunological assay Methods 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 238000011081 inoculation Methods 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 238000012482 interaction analysis Methods 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 229960001388 interferon-beta Drugs 0.000 description 1
• 102000002467 interleukin receptors Human genes 0.000 description 1
• 108010093036 interleukin receptors Proteins 0.000 description 1
• 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 1
• 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 1
• 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 description 1
• 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 229940039009 isoproterenol Drugs 0.000 description 1
• MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 229960001375 lactose Drugs 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940039781 leptin Drugs 0.000 description 1
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 108010052620 leukocyte endogenous mediator Proteins 0.000 description 1
• 150000002617 leukotrienes Chemical class 0.000 description 1
• 239000004571 lime Substances 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 238000001459 lithography Methods 0.000 description 1
• 208000007903 liver failure Diseases 0.000 description 1
• 210000002311 liver mitochondria Anatomy 0.000 description 1
• 230000008752 local inflammatory process Effects 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 230000002132 lysosomal effect Effects 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 229960003987 melatonin Drugs 0.000 description 1
• DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
• 238000010197 meta-analysis Methods 0.000 description 1
• 230000006680 metabolic alteration Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 229960001252 methamphetamine Drugs 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 210000004688 microtubule Anatomy 0.000 description 1
• 210000004939 midgestation embryo Anatomy 0.000 description 1
• 210000003470 mitochondria Anatomy 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
• 229960005181 morphine Drugs 0.000 description 1
• 101150029137 mutY gene Proteins 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 101150091879 neo gene Proteins 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 239000002687 nonaqueous vehicle Substances 0.000 description 1
• 231100000956 nontoxicity Toxicity 0.000 description 1
• 210000000633 nuclear envelope Anatomy 0.000 description 1
• 238000007899 nucleic acid hybridization Methods 0.000 description 1
• 239000002853 nucleic acid probe Substances 0.000 description 1
• 238000001821 nucleic acid purification Methods 0.000 description 1
• 238000011330 nucleic acid test Methods 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 210000003101 oviduct Anatomy 0.000 description 1
• 230000004783 oxidative metabolism Effects 0.000 description 1
• 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
• 230000020477 pH reduction Effects 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 208000028169 periodontal disease Diseases 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 230000006461 physiological response Effects 0.000 description 1
• 230000006343 physiological stress response Effects 0.000 description 1
• 230000001885 phytohemagglutinin Effects 0.000 description 1
• 238000002616 plasmapheresis Methods 0.000 description 1
• 229940012957 plasmin Drugs 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 102000030769 platelet activating factor receptor Human genes 0.000 description 1
• 230000010118 platelet activation Effects 0.000 description 1
• VJILEYKNALCDDV-OIISXLGYSA-N podocarpic acid group Chemical class OC=1C=C2[C@]3(CCC[C@@]([C@@H]3CCC2=CC1)(C(=O)O)C)C VJILEYKNALCDDV-OIISXLGYSA-N 0.000 description 1
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 229960002288 procaterol Drugs 0.000 description 1
• FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
• 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 229940070353 protamines Drugs 0.000 description 1
• 235000019833 protease Nutrition 0.000 description 1
• 230000004952 protein activity Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 239000012521 purified sample Substances 0.000 description 1
• 229960001285 quercetin Drugs 0.000 description 1
• 235000005875 quercetin Nutrition 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 239000011535 reaction buffer Substances 0.000 description 1
• 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 238000009877 rendering Methods 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 230000001850 reproductive effect Effects 0.000 description 1
• 238000002271 resection Methods 0.000 description 1
• 201000004193 respiratory failure Diseases 0.000 description 1
• 230000036387 respiratory rate Effects 0.000 description 1
• 230000003938 response to stress Effects 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 229930002330 retinoic acid Natural products 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 238000005070 sampling Methods 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 230000009919 sequestration Effects 0.000 description 1
• 208000037974 severe injury Diseases 0.000 description 1
• 230000009528 severe injury Effects 0.000 description 1
• 208000007056 sickle cell anemia Diseases 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 239000002356 single layer Substances 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 229940079832 sodium starch glycolate Drugs 0.000 description 1
• 239000008109 sodium starch glycolate Substances 0.000 description 1
• 229920003109 sodium starch glycolate Polymers 0.000 description 1
• 239000012453 solvate Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 229940032147 starch Drugs 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 229950003441 tebufelone Drugs 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 229960000195 terbutaline Drugs 0.000 description 1
• 229960000278 theophylline Drugs 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 229940113082 thymine Drugs 0.000 description 1
• 229960000187 tissue plasminogen activator Drugs 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 210000003437 trachea Anatomy 0.000 description 1
• NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
• 229960005342 tranilast Drugs 0.000 description 1
• 230000005758 transcription activity Effects 0.000 description 1
• 238000012085 transcriptional profiling Methods 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 229960001727 tretinoin Drugs 0.000 description 1
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
• 229940029284 trichlorofluoromethane Drugs 0.000 description 1
• 229960003500 triclosan Drugs 0.000 description 1
• 229940035670 tuftsin Drugs 0.000 description 1
• IESDGNYHXIOKRW-LEOABGAYSA-N tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 description 1
• 230000009452 underexpressoin Effects 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 208000009852 uremia Diseases 0.000 description 1
• 229940116269 uric acid Drugs 0.000 description 1
• 239000002550 vasoactive agent Substances 0.000 description 1
• 230000025033 vasoconstriction Effects 0.000 description 1
• 230000003639 vasoconstrictive effect Effects 0.000 description 1
• 239000005526 vasoconstrictor agent Substances 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 210000003135 vibrissae Anatomy 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 210000004340 zona pellucida Anatomy 0.000 description 1